Zdrowie i gospodarka · 11/07/2007
FDA Clears ARISTOCORT FORTE Injectable Suspension for Approval via Abbreviated New Drug Applications
The FDA has determined that ARISTOCORT FORTE Injectable Suspension (triamcinolone diacetate, 40 mg/mL) was not withdrawn from sale due to safety or effectiveness concerns, paving the way for approval of abbreviated new drug applications (ANDAs) for this formulation.
Source: Federal Register — Food and Drug AdministrationOpen original release →